Who
Michael Parini
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Biogen; EVP, Chief Adm, Leg & BD Off, Vertex Pharmaceuticals.
In numbers
- Trades disclosed
- 288
- Buys
- 0
- Sells
- 63
- Bought
- $0
- Sold
- $45.4M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 4 Jan 2016
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 1 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,405 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,405 at $0.00 | filing |
| 25 Feb 2021filed 26 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $137K646 at $211.58 | filing |
| 25 Feb 2021filed 26 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $287K1,348 at $213.04 | filing |
| 25 Feb 2021filed 26 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $146K680 at $214.28 | filing |
| 25 Feb 2021filed 26 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $77K354 at $216.26 | filing |
| 24 Feb 2021filed 26 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $526K2,416 at $217.57 | filing |
| 18 Feb 2021filed 19 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $212K1,007 at $210.08 | filing |
| 18 Feb 2021filed 19 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $988K4,666 at $211.83 | filing |
| 18 Feb 2021filed 19 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $415K1,952 at $212.56 | filing |
| 18 Feb 2021filed 19 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $43K200 at $213.45 | filing |
| 17 Feb 2021filed 19 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.3M6,240 at $211.75 | filing |
| 11 Feb 2021filed 16 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $803K3,818 at $210.43 | filing |
| 11 Feb 2021filed 16 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $63K300 at $211.21 | filing |
| 11 Feb 2021filed 16 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $42K200 at $211.97 | filing |
| 10 Feb 2021filed 12 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $549K2,563 at $214.16 | filing |
| 5 Feb 2021filed 9 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $167K1,930 at $86.52 | filing |
| 5 Feb 2021filed 9 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $415K1,930 at $215.00 | filing |
| 5 Feb 2021filed 9 Feb 2021 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,930 at $0.00 | filing |
| 3 Feb 2021filed 5 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —8,438 at $0.00 | filing |
News
Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Michael Parini; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.